Symyx completes Integrity Biosolution acquisition
This article was originally published in Scrip
The US R&D integration firmSymyx Technologies has acquired the biologics formulation company Integrity Biosolution for an undisclosed cash sum. The acquisition will allow Symyx's research services division to offer both biologics and chemical formulation services, it says. In the second quarter ended June 30th, Symyx had revenues of $40.7 million and made a net loss of $1.5 million; it had a cash balance of $88 million at the end of the quarter. Symyx's technology platform includes electronic lab notebooks, software for integrating workflows and other R&D services.